| Theme | Hilar and Intrahepatic Cholangiocarcinoma | |
|---|---|---|
| Title | Cholangiocellular Carcinoma | |
| Publish Date | 2011/12 | |
| Author | Yoshihiro Sakamoto | Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author | Suguru Yamashita | Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author | Taku Aoki | Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author | Kiyoshi Hasegawa | Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author | Yasuhiko Sugawara | Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author | Norihiro Kokudo | Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| [ Summary ] | Cholangiocellular carcinoma (CCC, i. e., intrahepatic cholangiocarcinoma) is a primary hepatic cancer, similar to hepatocellular carcinoma, arising from the 2nd or higher order branch of the bile duct. Histopathologically, CCC is a form of adenocarcinoma and can involve adjacent structures or exhibit nodal metastasis. Patients with CCC in the peripheral liver are asymptomatic, while patients with CCC involving the hepatic hilum present with obstructive jaundice. CCC exhibits irregular boundaries between surrounding hepatic parenchyma and hypovascular tissue, as observed in diagnostic imaging. Macroscopically, the mass forming type and the mass forming + periductal infiltrating type are dominant (90 % of all cases). The prognosis for patients with the latter type is worse than that with former type. The first treatment should be surgical resection. However, clinical evidence concerning the efficacy of chemotherapy is limited. Important prognostic factors after surgical resection are nodal metastasis, number of tumors and serum CA19 -9 levels. | |